Stock Ratings / Health Care / ARVN / earnings

DMAC (34) INDP (36) CBIO (44) OCS (58) ⌘ Pro Terminal →

Arvinas Inc. (ARVN) Next Earnings Date & Expected ±10% Move

$7.90 +3.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Arvinas Inc. (ARVN) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $516.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARVN)Realized 20D OHLCV Swing Band: ±10%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±10% Swing Band

±$0.79 Expected Swing

MODEL EARNINGS SETUP GAUGE

ARVN Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $4.25 • YoY Revenue Growth: -0.3%

Model Bullish Setup (37/100)Model Risk Weight (63/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$262.6M	-$81.0M	-$275.7M	52%
FY 2024	2024-12-31	$263.4M	-$199.0M	-$261.1M	52%
FY 2023	2023-12-31	$78.5M	-$367.0M	-$347.8M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARVN)

✓Walkthrough of ARVN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ARVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.20%📐 HORIZONTAL RANGE

2026-10-30O $7.90H $8.03L $7.66C $7.90VOL 1.13M

RES: $10.87SUP: $6.52SMA50: $8.10SMA200: $9.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARVN Butterfly Map → + Track ARVN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -0.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ARVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARVN)

Health Care Rank #745 of 1016 ⚔️ DMAC vs ARVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARVN vs. DMAC, INDP, CBIO, OCS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Arvinas Inc. (ARVN) ranks #745 by composite RQD confidence (37/100, grade D-) and #443 by equity capitalization ($516.6M). Within this direct 5-issuer industry benchmark cohort, ARVN leads on earnings valuation at N/A trailing P/E, while ARVN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ARVN at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ARVN ACTIVE Arvinas Inc.	D-	37/100	—	—	-32.1%	+3.95%	$516.6M	Benchmark Subject
DMAC DiaMedica Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.05%	$513.4M	/dmac-vs-arvn →
INDP Indaptus Therapeutics Inc.	D-	36/100	—	—	-35.0%	+0.30%	$513.0M	/indp-vs-arvn →
CBIO Crescent Biopharma Inc.	D	44/100	—	—	-35.0%	+4.22%	$522.6M	/cbio-vs-arvn →
OCS Oculis Holding AG	D+	58/100	—	—	—	+3.26%	$507.5M	/ocs-vs-arvn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001655759

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arvinas Inc. (ARVN) reported GAAP revenue of $262.6M (-0.3% vs. FY2024 revenue of $263.4M , and +234.5% cumulative change since FY2023) , GAAP net income of -$81.0M, operating cash flow of -$273.8M, and free cash flow of -$275.7M (-5.6% YoY). On the balance sheet, ARVN closed FY2025 with $717.9M in total assets against $400.0K in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$262.6M	-$81.0M	-$273.8M	-$275.7M	$717.9M	$400.0K
FY2024 (FY)	2024-12-31	$263.4M	-$199.0M	-$259.3M	-$261.1M	$1.09B	$600.0K
FY2023 (FY)	2023-12-31	$78.5M	-$367.0M	-$347.8M	-$347.8M	—	—

3. ARVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Arvinas Inc. (NASDAQ: ARVN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $7.90 (+3.95% 1D, market cap $516.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARVN ranks #745 in composite RQD confidence.

How does ARVN compare to DMAC and INDP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARVN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.1%. By comparison, DMAC (DiaMedica Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M) and INDP (Indaptus Therapeutics Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $513.0M). Among the 5-stock peer group, ARVN leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ARVN?

Per ARVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001655759), Arvinas Inc. generated $262.6M in revenue (-0.3% YoY), -$81.0M in net income, and -$275.7M in free cash flow against $717.9M in total assets and $400.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ARVN trading relative to its 50-day, 200-day, and 52-week technical levels?

ARVN last traded at $7.90 (+3.95% on volume of 863,848 shares), positioning the stock -2.47% below its 50-day simple moving average ($8.10) and -18.47% below its 200-day simple moving average ($9.69). Across its 52-week range of $6.74 to $14.51, ARVN sits at the 14.9% percentile with a 14-day RSI of 54.6 (NEUTRAL RANGE) and an implied next-earnings move of ±10.0% ($7.11 to $8.69).